In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks : pooled analysis of two Scandinavian trials. / Dalgard, O.; Bjoro, K.; Larsen, Helmer Ring; Verbaan, H.

I: European Journal of Gastroenterology and Hepatology, Bind 22, Nr. 5, 01.05.2010, s. 552-556.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Dalgard, O, Bjoro, K, Larsen, HR & Verbaan, H 2010, 'In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials', European Journal of Gastroenterology and Hepatology, bind 22, nr. 5, s. 552-556.

APA

Dalgard, O., Bjoro, K., Larsen, H. R., & Verbaan, H. (2010). In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepatology, 22(5), 552-556.

Vancouver

Dalgard O, Bjoro K, Larsen HR, Verbaan H. In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials. European Journal of Gastroenterology and Hepatology. 2010 maj 1;22(5):552-556.

Author

Dalgard, O. ; Bjoro, K. ; Larsen, Helmer Ring ; Verbaan, H. / In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks : pooled analysis of two Scandinavian trials. I: European Journal of Gastroenterology and Hepatology. 2010 ; Bind 22, Nr. 5. s. 552-556.

Bibtex

@article{8c3ff6e8fb5549e0a5758d1ec32e1965,
title = "In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks: pooled analysis of two Scandinavian trials",
keywords = "Former Faculty of Pharmaceutical Sciences",
author = "O. Dalgard and K. Bjoro and Larsen, {Helmer Ring} and H. Verbaan",
year = "2010",
month = "5",
day = "1",
language = "English",
volume = "22",
pages = "552--556",
journal = "European Journal of Gastroenterology and Hepatology",
issn = "0954-691X",
publisher = "Lippincott Williams & Wilkins, Ltd.",
number = "5",

}

RIS

TY - JOUR

T1 - In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks

T2 - pooled analysis of two Scandinavian trials

AU - Dalgard, O.

AU - Bjoro, K.

AU - Larsen, Helmer Ring

AU - Verbaan, H.

PY - 2010/5/1

Y1 - 2010/5/1

KW - Former Faculty of Pharmaceutical Sciences

M3 - Journal article

VL - 22

SP - 552

EP - 556

JO - European Journal of Gastroenterology and Hepatology

JF - European Journal of Gastroenterology and Hepatology

SN - 0954-691X

IS - 5

ER -

ID: 33788426